Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Association Study of Gene Polymorphisms With Cardiac Performance

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2008 by University Hospital, Essen.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University Hospital, Essen
ClinicalTrials.gov Identifier:
NCT00730899
First received: August 4, 2008
Last updated: NA
Last verified: August 2008
History: No changes posted
  Purpose

The purpose of this study is to determine whether polymorphisms in G protein subunits, namely Galphas and Galphaq, are associated with altered cardiac performance in heart failure patients.


Condition
Genetic Polymorphism
Coronary Artery Disease
Hemodynamics

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Observational Association Study of G Protein Polymorphisms With Cardiac Performance in Coronary Artery Disease Patients Undergoing Coronary Artery Bypass Grafting

Further study details as provided by University Hospital, Essen:

Primary Outcome Measures:
  • genotype dependent change of hemodynamic variables [ Time Frame: one day ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • all cause mortality [ Time Frame: 60 days ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

whole blood


Estimated Enrollment: 500
Study Start Date: May 2008
Estimated Study Completion Date: June 2011
Estimated Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Detailed Description:

G Protein pathways plays a pivotal role in mediating positive inotropy and cardiac hypertrophy by transducing signals of neurohormones in cardiomyocytes. Single nucleotide polymorphisms (SNPs) in the G protein subunits Galphas and Galphaq have been shown to result in altered protein expression. We now want to examine whether G Protein polymorphisms alter NYHA functional class, and hemodynamic variables in patients with coronary artery disease scheduled for coronary artery bypass grafting .

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with coronary artery disease scheduled for coronary artery bypass grafting in the university hospital

Criteria

Inclusion Criteria:

  • clinical diagnosis of coronary artery disease
  • patients scheduled for coronary artery bypass grafting

Exclusion Criteria:

  • emergency operation
  • combined vitium
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00730899

Contacts
Contact: Ulrich H Frey, MD +49201723 ext 1401 ulrich.frey@uk-essen.de

Locations
Germany
University Hospital Recruiting
Essen, Nordrhein-Westfalen, Germany, 45147
Contact: Ulrich H Frey, MD    +49201723 ext 1401    ulrich.frey@uk-essen.de   
Principal Investigator: Jürgen Peters, MD         
Sponsors and Collaborators
University Hospital, Essen
Investigators
Study Director: Jürgen Peters, MD University Hospital, Essen
  More Information

Additional Information:
No publications provided

Responsible Party: Ulrich Frey, University Hospital Essen
ClinicalTrials.gov Identifier: NCT00730899     History of Changes
Other Study ID Numbers: HOT-001
Study First Received: August 4, 2008
Last Updated: August 4, 2008
Health Authority: Germany: Federal Ministry of Education and Research

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Heart Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on November 27, 2014